TELA Bio, Inc. (TELA) — Business Overview

---

Executive Summary

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company headquartered in Malvern, Pennsylvania, that designs, develops, and markets biologic and bio-synthetic soft tissue reinforcement products for hernia repair and plastic/reconstructive surgery. Founded in 2012 and public since 2019, TELA Bio is not a pre-revenue clinical biotech — it is a revenue-generating, FDA-cleared medical device company that sold $80.3 million of product in fiscal 2025, up 16% year-over-year, through a direct U.S. sales force supplemented by distributors in Europe.

The company's core innovation is its OviTex and OviTex PRS product families — "reinforced tissue matrices" (RTMs) that combine ovine (sheep)-derived extracellular matrix (ECM) with an embedded, minimal-mass polymer suture scaffold. This hybrid design is positioned as a middle path between fully permanent synthetic mesh (higher mechanical strength, higher long-term complication/infection risk) and fully biologic matrices (better biocompatibility, weaker long-term mechanical support). TELA Bio is a small-cap, sub-scale competitor in a market dominated by much larger, better-capitalized device and pharma conglomerates, and its investment case centers on continued share capture in hernia repair and expansion into plastic and reconstructive surgery indications, balanced against execution risk on its path to sustained profitability.

---

1. Core Business Model & How They Work

TELA Bio operates a classic direct-sales medical device commercialization model: a clinical/sales organization educates and supports surgeons, who select the product intra-operatively, with hospitals and ambulatory surgery centers (ASCs) as the purchasing and reimbursement gatekeepers.

[ TELA Bio Direct Sales Reps ]  +  [ Independent Distributors (select EU/UK markets) ]
                 │  clinical education, OR case support, surgeon training
                 ▼
     [ Surgeons — General, Hernia, Plastic & Reconstructive ]
                 │  select OviTex / OviTex PRS / LIQUIFIX intra-operatively
                 ▼
   [ Hospitals & Ambulatory Surgery Centers (ASCs) ]
                 │  procurement via national GPO contracts; case reimbursed
                 │  under bundled MS-DRG hospital payment (not separately billed)
                 ▼
        [ Patient Outcome Data / Case Follow-Up ]
                 │  feeds surgeon advocacy, peer-reviewed publications,
                 │  and key-opinion-leader (KOL) network expansion
                 └────────────────────► reinforces repeat utilization

Key Operational Drivers

1. Surgeon-Led Adoption: Because the mesh/matrix choice is made by the operating surgeon, not a hospital purchasing committee, TELA Bio's commercial strategy is built around clinical evidence generation, case support, and relationships with high-volume hernia and reconstructive surgeons.
2. GPO & Reimbursement Access: The company has contracted with three national group purchasing organizations (GPOs) covering OviTex and OviTex PRS and continues to add GPO and integrated delivery network (IDN) agreements — a necessary, though not sufficient, condition for hospital formulary access.
3. Indication Expansion as Growth Lever: Rather than relying on a single blockbuster product, TELA Bio grows by adding configurations (e.g., OviTex IHR for inguinal hernia, launched in the U.S. in April 2024 and Europe in June 2025) and pursuing new reconstructive indications (e.g., an ongoing IDE study in breast reconstruction).
4. Tuck-In Commercial Agreements: TELA Bio supplements its own portfolio with distributed third-party products — e.g., LIQUIFIX mesh fixation devices (distributed under agreement with Advanced Medical Solutions, U.S. launch March 2024) — to round out the surgeon's toolkit without bearing full R&D cost.

---

2. Product Portfolio

---

3. Competitive Landscape

TELA Bio competes against far larger, multi-billion-dollar medical device and biopharmaceutical companies in both of its target markets. Its strategic positioning rests on being a hybrid ("best of both worlds") alternative to pure-synthetic and pure-biologic incumbents, rather than competing head-on with either on their own terms.

                    SOFT-TISSUE REINFORCEMENT POSITIONING MATRIX
┌──────────────────────────────────────────────────────────────────────┐
│ High                                                                  │
│  ▲      [AbbVie/Allergan — Strattice, AlloDerm]                       │
│  B      [Integra LifeSciences — SurgiMend, DuraSorb]                  │
│  I      [MTF Biologics — FlexHD]  [RTI Surgical — Cortiva]            │
│  O                                                                    │
│  L                    [TELA Bio — OviTex / OviTex PRS]                │
│  O                       (hybrid ECM + polymer scaffold)              │
│  G                                                                    │
│  I                                         [BD/Bard — Phasix,         │
│  C                                           Ventralight ST,          │
│                                               GalaFLEX]               │
│  │                                                                    │
│ Low                                             [Generic permanent    │
│  │                                               synthetic mesh]      │
│  └────────────────────────────────────────────────────────────────►  │
│   Low         LONG-TERM MECHANICAL REINFORCEMENT STRENGTH        High │
└──────────────────────────────────────────────────────────────────────┘

Named Competitors (per TELA Bio's own SEC disclosures)

• Becton, Dickinson and Company (via Bard) — Phasix, Ventralight ST, GalaFLEX: resorbable and permanent synthetic mesh options competing directly in hernia repair.
• AbbVie (via Allergan) — Strattice (hernia/soft tissue), AlloDerm (plastic/reconstructive): leading acellular dermal matrix (ADM) biologic competitor.
• Integra LifeSciences — SurgiMend, DuraSorb: fetal bovine- and synthetic-derived matrices competing primarily in reconstructive and hernia applications.
• MTF Biologics — FlexHD; RTI Surgical — Cortiva: allograft-based acellular dermal matrices used in plastic/reconstructive surgery.

Beyond named 10-K competitors, the broader soft-tissue reinforcement and hernia-repair landscape also includes 3M/Solventum (formerly KCI/Acelity) and Cook Biotech (Biodesign), both active in adjacent biologic scaffold and wound/soft-tissue markets. Virtually all of these competitors are substantially larger and better capitalized than TELA Bio, giving them deeper sales forces, broader GPO leverage, and greater capacity to fund head-to-head clinical studies.

---

4. Strategic Strengths & Risks

Strategic Strengths

• Differentiated Hybrid Technology: OviTex's combination of ovine ECM and embedded polymer suture is a genuine point of clinical differentiation versus "all-synthetic" or "all-biologic" alternatives, supported by a growing base of peer-reviewed outcomes literature.
• Consistent Double-Digit Revenue Growth: Revenue has grown from roughly $58 million (2023) to $69.3 million (2024, +19%) to $80.3 million (2025, +16%) — a demonstrated, multi-year commercial ramp rather than a one-time pop.
• Expanding Indication Set: The 2024–2025 launches of OviTex IHR (inguinal hernia) in the U.S. and Europe, plus an active IDE study in breast reconstruction, give the company multiple avenues for growth beyond its original ventral hernia base.
• Newly Secured Growth Capital: A credit facility with Perceptive Advisors (up to $70.0 million — $60.0 million funded at closing, plus a further $10.0 million available through April 2027 subject to revenue conditions) extends the company's financial flexibility without near-term equity dilution.

Strategic Risks

• Path to Profitability Is Not Yet Achieved: TELA Bio posted a net loss of $38.8 million in 2025 against an accumulated deficit of $397.6 million, and management's own framing — that current cash "keeps us on a path to profitability without the need to raise additional capital" — is itself an acknowledgment that profitability is a future, not current, state. While there is no formal going-concern qualification in the FY2025 10-K, the combination of persistent net losses, a large accumulated deficit, and reliance on a newly drawn debt facility is a risk profile characteristic of smaller commercial-stage medtechs that have not yet crossed into sustainable self-funding — a risk worth monitoring even absent an explicit audit flag.
• 2025 Guidance Miss: Management had guided to 23%–27% revenue growth for 2025 but delivered 16%, a meaningful shortfall that raises questions about near-term execution and sales-force productivity ahead of 2026 guidance of "at least 8%" growth — itself a deceleration.
• Scale Disadvantage vs. Competitors: Every named competitor (BD, AbbVie, Integra, MTF Biologics, RTI Surgical) is dramatically larger, with broader portfolios, deeper GPO relationships, and far greater capacity to absorb pricing pressure or fund competing clinical trials.
• Reimbursement Exposure: Hospital reimbursement for hernia repair flows through bundled MS-DRG payments rather than separate device billing, meaning hospital cost-consciousness directly pressures the price TELA Bio can realize per unit.
• Debt Covenant Risk: Access to the second tranche of the Perceptive credit facility is conditioned on net revenue thresholds, tying the company's financial flexibility to continued execution against growth targets it has recently missed.

---

5. Financial Overview

Note: TELA Bio's gross margin has held steady in the high-60s percentage range even as revenue scales, indicating that the core unit economics of OviTex are sound; the persistent net losses are primarily a function of operating expense scale (sales force build-out, clinical studies, and SG&A) relative to a still-sub-$100 million revenue base, rather than a product-economics problem.

---

6. Summary Conclusion

TELA Bio is a legitimate, FDA-cleared, revenue-generating commercial-stage medtech company — not a speculative pre-revenue biotech — with a differentiated hybrid biologic/bio-synthetic product platform in OviTex and OviTex PRS. The company has compounded revenue at a mid-teens-to-high-teens rate for three consecutive years and recently secured incremental growth capital, but it remains sub-scale relative to every named competitor and has not yet reached profitability, missing its own 2025 growth guidance along the way. The investment thesis hinges on whether continued indication expansion (inguinal hernia, eventual breast reconstruction) and GPO penetration can sustain double-digit growth long enough to convert TELA Bio's healthy gross margins into operating profitability before competitive or capital-market pressure forces a reset.